Axsome Therapeutics, Inc. · NASDAQ:AXSM
Axsome Therapeutics — Merger or Acquisition (March 2022)
12 slides from Axsome Therapeutics's merger presentation, Mar 28, 2022
Slide 1: Expanding Axsome's Leadership in Neuroscience: Axsome to Acquire Sunosi from Jazz
Expanding Axsome’s Leadership in Neuroscience Axsome to Acquire Sunosi® (solriamfetol) from Jazz Pharmaceuticals March 28, 2022 Exhibit 99.2
Slide 2: Forward Looking Statements & Safe Harbor
Forward Looking Statements & Safe Harbor Certain information contained in this presentation may include “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “
Slide 3: Expanding Axsome's Leadership in Neuroscience
Expanding Axsome’s Leadership in Neuroscience Oral NMDA Receptor Antagonist with Multimodal Activity MoSEIC™ COX-2 Pref. Inhibitor + 5-HT1B/1D Agonist DNRI Dopamine Norepinephrine Reuptake Inhibitor Major Depressive Disorder Migraine EDS Associated with Narcolepsy or OSA NDA under Review NDA under R
Slide 4: Strong Strategic Fit and Financial Benefits
Strong Strategic Fit and Financial Benefits Adds a Third High-potential Commercial-stage CNS Asset to Axsome Portfolio Transaction will immediately accelerate Axsome’s transition to a global commercial entity ahead of potential near-term launches of AXS-05 in depression and AXS-07 in migraine in 202
Slide 5: Sunosi Overview
Sunosi Overview Differentiated Profile First and only FDA-approved dual-acting DNRI to treat EDS in adults with narcolepsy or OSA Improves wakefulness and reduces EDS Performance to Date Launched in 2019 in the U.S., and 2020 in the E.U. 2021 sales of $57.9M, year-over-year growth of 104% 90% of com
Slide 6: Sunosi Has Substantial Revenue Potential
Sunosi Has Substantial Revenue Potential >$1 billion peak potential with current and potential future indications Growth in EDS EDS in Narcolepsy or OSA Potential New Neuroscience Indications Narcolepsy remains an unmet need, and OSA has an extremely low drug treatment rate (~6%) ~12 million diagnos
Slide 7: Target Sunosi Prescribers Overlap with Existing Axsome Portfolio
Target Sunosi Prescribers Overlap with Existing Axsome Portfolio Sleep Specialist Psychiatrist Neurologist EDS in OSA and Narcolepsy Key Prescribers Prescriber Overlap with Existing Axsome Portfolio AXS-05 AXS-07 AXS-12 Cataplexy in Narcolepsy Phase 3 Ongoing Major Depressive Disorder NDA under Revi
Slide 8: Digital Centric Commercialization (DCC)
Digital Centric Commercialization (DCC)TM Real-time Data Seamless Integration Sophisticated Analytics Targeted Deployment Dedicated Digital Engagement team Insight-driven, quick analyses of real-time data from customer engagements Fully integrated data, systems infrastructure, and Veeva partnership
Slide 9: Transaction Specifics
Transaction Specifics Asset and Territory Sunosi (solriamfetol) Worldwide rights except for certain Asian markets including China, Korea, and Japan Financial Terms Jazz to receive from Axsome: $53 million upfront; high single-digit royalty for the current indication and mid single-digit royalty for
Slide 10: Transformational Acquisition to Deliver Significant Value
Transformational Acquisition to Deliver Significant Value Anticipated to deliver substantial shareholder value. Sunosi will be immediately revenue generating upon closing, and is expected to be breakeven to Axsome’s operating plan in 2023 and substantially accretive thereafter Potential for rapid de
Slide 11: Robust, Late-Stage Neuroscience Pipeline
Robust, Late-Stage Neuroscience Pipeline EDS Associated with Narcolepsy or OSA Potential New Indications Product Candidate MOA Phase 1 Phase 2 Phase 3 NDA NMDA receptor antagonist with multimodal activity MoSEIC™ COX-2 pref. inhibitor + 5-HT1B/1D agonist Highly selective NE reuptake inhibitor Highly
Slide 12: Q&A
axsome Q&A
Axsome Therapeutics — Merger or Acquisition (March 2022) on 6ix